Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: a proof-of-concept study
Conclusions:
Combined glucose, fructose and sorbitol HMBT has the potential to optimize cs-SIBO diagnosis. Furthermore, the majority of patients with cs-SIBO seem to benefit from rifaximin therapy regardless of its carbohydrate specificity.
Source: Therapeutic Advances in Gastroenterology - Category: Gastroenterology Authors: Enko, D., Halwachs-Baumann, G., Stolba, R., Mangge, H., Kriegshäuser, G. Tags: Original Research Source Type: research